TY - JOUR
T1 - B-cell function after unrelated umbilical cord blood transplantation using a minimal-intensity conditioning regimen in patients with X-SCID
AU - Kumaki, Satoru
AU - Sasahara, Yoji
AU - Kamachi, Yoshiro
AU - Muramatsu, Hideki
AU - Morio, Tomohiro
AU - Goi, Kumiko
AU - Sugita, Kanji
AU - Urabe, Tomonari
AU - Takada, Hidetoshi
AU - Kojima, Seiji
AU - Tsuchiya, Shigeru
AU - Hara, Toshirou
N1 - Funding Information:
Acknowledgments We thank Dr. David Cosman for critical reading of this manuscript. This study was supported by the Japanese Research Group on Primary Immunodeficiency Diseases, supported by the Ministry of Health, Labour and Welfare in Japan.
PY - 2013/9
Y1 - 2013/9
N2 - Patients with X-linked severe combined immunodeficiency (X-SCID) suffer from severe and persistent infections, and usually die early in life unless treated by hematopoietic stem cell transplantation. If a patient has an HLA-identical sibling donor, preparative conditioning is not necessary for T-cell engraftment and B-cell function. However, in the absence of such a donor, long-term reconstitution of full B-cell function is often problematic, leading in many cases to a lifetime requirement for immunoglobulin replacement therapy. Preparative myeloablative conditioning has been shown to improve long-term B-cell function, but may aggravate pre-existing infection and transplant-related toxicity. It is thus important to determine the minimum intensity of conditioning that assures immunoglobulin production. In the present study, we performed reduced-intensity conditioning (RIC), consisting of fludarabine 125 mg/m2 and melphalan 80 mg/m2, prior to unrelated umbilical cord blood transplantation (UCBT) for five patients with X-SCID, none of them had an HLA-identical donor. Four patients survived more than 4 years without sequelae, and none required long-term immunoglobulin replacement therapy. One patient succumbed to sepsis in conjunction with severe GVHD. Our result demonstrates that the RIC regimen described above in combination with UCBT is an effective and less toxic conditioning to correct B-cell function in patients with X-SCID.
AB - Patients with X-linked severe combined immunodeficiency (X-SCID) suffer from severe and persistent infections, and usually die early in life unless treated by hematopoietic stem cell transplantation. If a patient has an HLA-identical sibling donor, preparative conditioning is not necessary for T-cell engraftment and B-cell function. However, in the absence of such a donor, long-term reconstitution of full B-cell function is often problematic, leading in many cases to a lifetime requirement for immunoglobulin replacement therapy. Preparative myeloablative conditioning has been shown to improve long-term B-cell function, but may aggravate pre-existing infection and transplant-related toxicity. It is thus important to determine the minimum intensity of conditioning that assures immunoglobulin production. In the present study, we performed reduced-intensity conditioning (RIC), consisting of fludarabine 125 mg/m2 and melphalan 80 mg/m2, prior to unrelated umbilical cord blood transplantation (UCBT) for five patients with X-SCID, none of them had an HLA-identical donor. Four patients survived more than 4 years without sequelae, and none required long-term immunoglobulin replacement therapy. One patient succumbed to sepsis in conjunction with severe GVHD. Our result demonstrates that the RIC regimen described above in combination with UCBT is an effective and less toxic conditioning to correct B-cell function in patients with X-SCID.
KW - Fludarabine/melphalan
KW - Reduced-intensity conditioning
KW - Umbilical cord blood transplantation
KW - X-SCID
UR - http://www.scopus.com/inward/record.url?scp=84884673825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884673825&partnerID=8YFLogxK
U2 - 10.1007/s12185-013-1408-7
DO - 10.1007/s12185-013-1408-7
M3 - Article
C2 - 23955111
AN - SCOPUS:84884673825
SN - 0925-5710
VL - 98
SP - 355
EP - 360
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 3
ER -